Physician Wealth Advisors’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$13.9K Buy
47
+4
+9% +$1.05K ﹤0.01% 811
2026
Q2
$9.8K Buy
43
+13
+43% +$2.32K ﹤0.01% 883
2026
Q1
$5.18K Hold
30
– – ﹤0.01% 994
2025
Q4
$5.98K Hold
30
– – ﹤0.01% 920
2025
Q3
$4.69K Buy
30
+3
+11% +$476 ﹤0.01% 939
2025
Q2
$4.1K Buy
27
+23
+575% +$3.07K ﹤0.01% 849
2025
Q1
$603 Buy
+4
New +$671 ﹤0.01% 1339

Other funds holding CRL

Physician Wealth Advisors's CRL Position: Q3 2026 in Review

Physician Wealth Advisors increased its Charles River Laboratories (CRL) stake by 9.3% in Q3 2026, buying an estimated $1.05K and bringing the position to 47 shares worth $13.9K. The position accounts for ﹤0.01% of the portfolio, ranked #811.

Physician Wealth Advisors first reported a position in CRL in Q1 2025 and has held it in 7 quarters since. 515 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Physician Wealth Advisors held 47 shares of Charles River Laboratories worth $13.9K as of Q3 2026.
  • Physician Wealth Advisors bought 4 Charles River Laboratories shares in Q3 2026, an estimated $1.05K.
  • Charles River Laboratories made up ﹤0.01% of Physician Wealth Advisors's portfolio in Q3 2026, its #811 holding.
  • Physician Wealth Advisors first reported a position in Charles River Laboratories in Q1 2025 and has held it in 7 quarters since.
  • 515 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Physician Wealth Advisors's 13F filing for Q3 2026, filed 20 Oct 2026.